कंपनी का अवलोकन
Nkarta, Inc. (NKTX) operates as a clinical-stage biopharmaceutical entity focused on the research and development of natural killer cell therapies designed for cancer and autoimmune disease treatment. The company functions within the Healthcare sector and specifically within the Biotechnology industry, where it leverages biological processes to create therapeutic interventions. Nkarta's current market capitalization stands at $165.39M, employing a workforce of 108 individuals to advance its lead product candidate, NKX019. The valuation indicates a mid-sized enterprise typical of clinical-stage biotechnology firms that have not yet generated significant commercial revenue to drive a larger market cap, reflecting the high capital expenditure required to progress candidates from Phase 1 clinical trials toward commercialization.
वित्तीय स्वास्थ्य
The company reports a net income of $-104,084,000 for the trailing twelve months, while EBITDA is recorded at $-106,645,000, highlighting a significant operational loss that consumes the entirety of its reported revenue which is listed as N/A. The gap between revenue and net income reveals a cost structure where research, development, and clinical trial expenses far exceed any current sales income, a characteristic pattern for clinical-stage biopharmaceutical companies. Free cash flow stands at $-53,593,752, indicating that the company is burning through its cash reserves to fund its pipeline rather than generating liquidity from operations. Gross margin, operating margin, and profit margin are all recorded as 0.0%, which signifies that the company is currently operating at a loss where costs have not yet been offset by commercial sales. Despite these deficits, the company holds $276.28M in cash against $76.42M in debt, resulting in a debt-to-equity ratio of 24.47. Although the debt-to-equity ratio appears high numerically, the substantial cash position relative to debt suggests the balance sheet is well-capitalized for a development-stage entity rather than being conservatively leveraged in a traditional sense. The current ratio of 12.69 indicates exceptionally strong short-term liquidity, suggesting the company has more than enough current assets to cover its short-term obligations without immediate distress. Return on Equity is -28.9% and Return on Assets is -16.0%, metrics that reflect the inherent financial reality of a company reinvesting all earnings back into development rather than distributing them, thereby preventing positive returns on capital in the current phase.
मूल्यांकन आकलन
The trailing P/E ratio is listed as N/A due to the lack of positive net income, while the forward P/E is -1.30, implying that the market is pricing in continued negative earnings expectations for the near future. The price-to-book ratio is 0.53, indicating that the market values the company at significantly less than its book value, a common valuation characteristic for biotechnology firms with intangible assets like intellectual property that are not fully captured on the balance sheet. The price-to-sales ratio is N/A because there is no significant sales data available, and the EV/EBITDA stands at 0.32, suggesting a very low enterprise value relative to earnings before interest, taxes, depreciation, and amortization, though the metric is distorted by negative earnings. The stock has a 52-week high of $2.81 and a 52-week low of $1.42, placing the current trading range within a band where the asset has shown substantial volatility typical of small-cap biotechnology stocks. The beta value of 0.67 indicates that the stock price is less volatile than the broader market, moving with 33% less intensity than the overall market index, which provides a measure of relative stability for a company with such a small market cap.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, reflecting the absence of commercial revenue streams necessary to calculate growth rates in the current fiscal period. Since the company is not currently profitable, it does not pay dividends, resulting in a dividend yield of N/A and a payout ratio of 0.0%. Consequently, the company is not distributing income to shareholders but is instead retaining all available capital to fund ongoing research and development activities. The overall growth and income profile for Nkarta, Inc. is defined entirely by its clinical development progress rather than financial expansion metrics, as the business model relies on future commercialization success to transition from a loss-making clinical-stage entity to a revenue-generating biopharmaceutical company.